BayWa's €107 Million Payment Buys Time, But No Solutions

A €107 million cash injection from the sale of its Cefetra business unit is set to hit BayWa's accounts by the end of April. This sum, however, does little more than provide temporary breathing room in the German conglomerate's fraught restructuring. The payment serves as a crucial bargaining chip with creditor banks DZ Bank and HVB, whose approval is required to extend a standstill agreement until autumn 2026. Without their consent, the restructuring plan finalized under Germany's StaRUG law in May 2025 would lose its legal foundation.

The company's shares currently trade at €13.60, having lost nearly 19% since the start of the year and sitting roughly 20% below their 200-day moving average. This technical weakness reflects a corporation battling on multiple fronts, with a complete picture of its financial health not expected before late 2026.

A Cascade of Crises

The core of BayWa's trouble is a €4 billion debt reduction target by 2028. Asset sales to date, including the Cefetra divestment, have trimmed liabilities by €1.3 billion—just under a third of the goal. The original centerpiece, a €1.7 billion deal to sell a 51% stake in its renewable energy subsidiary BayWa r.e., collapsed after the US cut renewable energy subsidies in early 2025. This failure forced a complete revaluation of the unit, which is a primary reason the audited group financial statements for 2025 are delayed until the fourth quarter of 2026.

Attention now turns to the potential sale of BayWa's nearly 74% stake in New Zealand fruit grower T&G Global. Goldman Sachs is managing the process, with private equity firms Roc Partners, Paine Schwartz, and Hancock cited as potential bidders. T&G, which returned to a net profit of $16 million on $1.3 billion in revenue in 2024, could fetch around €300 million. The process is complicated by minority shareholder Joy Wing Mau, which holds roughly 20% of T&G.

Should investors sell immediately? Or is it worth buying BayWa?

Governance and Legal Quagmires

Parallel to the financial strain, BayWa faces significant governance and legal challenges. The supervisory board is undergoing a transformation with the recent departures of Monika Hohlmeier and Michael Höllerer, and Monique Surges set to follow at the end of May. The board has also tightened controls, lowering the threshold for transactions requiring its approval from €200 million to €50 million.

A more severe issue involves the company's former auditor. The audit oversight body Apas has initiated proceedings against PricewaterhouseCoopers (PwC). The allegation is that PwC issued an unqualified audit opinion for 2023 without highlighting existential risks to the company. BayWa is now seeking a new auditor from 2026 onwards and is examining concrete claims for damages against PwC, which will audit the 2025 accounts for the final time.

This regulatory action dovetails with legal threats from shareholders. Law firm TILP is preparing investor lawsuits based on a BaFin ruling that criticized BayWa for omitting material details about a billion-euro loan and refinancing risks for a €500 million bond in its management report. Shareholders who purchased stock between January 2022 and January 2026 are eligible to join the action.

Operational Overhaul and Banking Jitters

Internally, a drastic operational restructuring is underway. The company aims to consolidate around four core business areas, cut approximately 1,300 jobs, and reduce revenue to about €10 billion by the end of 2028. Management has already withdrawn its financial forecast for 2026 and lowered its adjusted EBITDA target for 2027 to around €140 million.

BayWa at a turning point? This analysis reveals what investors need to know now.

The depth of concern is palpable even among cooperative banks, traditionally supportive of the group. Lenders, including Bavarian cooperative banks, have already written down 60% of a €220 million Schuldschein loan in their 2024 annual accounts.

For investors, the path forward remains opaque. A credible revaluation of the company is impossible without both an audited annual report and a finalized agreement with creditor banks. Neither is anticipated before the autumn of 2026, leaving the market in a prolonged state of uncertainty. The upcoming €107 million provides a short-term lifeline, but it fails to address the fundamental €2.7 billion gap in the restructuring plan or the growing list of legal and governance headaches.

Ad

BayWa Stock: New Analysis - 17 April

Fresh BayWa information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BayWa analysis...

en | DE0005194005 | BAYWAS | boerse | 69184875 |